Science & Technology
Improving the effectiveness of anti-tuberculosis drugs by developing a point-of-care therapeutic drug monitoring system for areas with limited medical resources
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43AI181155-01
Award Ceiling
$266K
Award Floor
$266K
Close Date
Jan 31, 2025
Total Funding
$266K
Expected Awards
1
Posted Date
Feb 12, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-1R43AI181155-01
Description
SBIR Phase Phase I award: "Improving the effectiveness of anti-tuberculosis drugs by developing a point-of-care therapeutic drug monitoring system for areas with limited medical resources" awarded to GLUCOSENTIENT INC in CHAMPAIGN, Illinois. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $265,773. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.